Core Viewpoint - The National Medical Products Administration (NMPA) has included the first-in-class EGFR x HER3 dual antibody ADC, izabren (BL-B01D1), developed by Bai Li Tian Heng, in the list of breakthrough therapies for the treatment of platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer patients [1] Group 1 - The drug izabren is recognized as a new concept and is the only one currently in Phase III clinical trials [1] - A total of six indications for izabren have been included in the breakthrough therapy list by the drug review center [1]